<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29873" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tardive Dyskinesia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vasan</surname>
            <given-names>Sarayu</given-names>
          </name>
          <aff>UCLA - Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padhy</surname>
            <given-names>Ranjit K.</given-names>
          </name>
          <aff>UCLA - Kern Medical</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sarayu Vasan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ranjit Padhy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29873.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tardive dyskinesia is a syndrome that includes a group of iatrogenic movement disorders caused by the blockade of dopamine receptors. The movement disorders include akathisia, dystonia, buccolingual stereotypy, myoclonus, chorea, tics, and other abnormal involuntary movements, which are commonly caused by the long-term use of typical antipsychotics. However, several other medications are also associated with tardive dyskinesia. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) defines tardive dyskinesia as a medication-induced movement disorder that persists despite discontinuation or change of the medications. As per DSM-V, to confirm a diagnosis of tardive dyskinesia, symptoms must persist for a month after discontinuation of the drug. This activity reviews tardive dyskinesia and highlights the role of the interprofessional team in recognizing and managing patients affected by this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the pathophysiology of tardive dyskinesia.</p></list-item><list-item><p>Describe exam findings consistent with tardive dyskinesia.</p></list-item><list-item><p>Outline management strategies for tardive dyskinesia.</p></list-item><list-item><p>Summarize strategies to educate interprofessional teams on common etiologies of tardive dyskinesia as well as common presentations so that efforts can be made to prevent it from developing in the first place and stop it from progressing if it has already developed.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29873&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29873">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29873.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tardive dyskinesia (TD) is a syndrome that&#x000a0;encompasses a&#x000a0;constellation of iatrogenic movement disorders caused by the antagonism of dopamine receptors. The movement disorders include akathisia, dystonia, buccolingual stereotypy, chorea, tics, and other abnormal involuntary movements. Most often, these dyskinetic disorders precipitate following chronic antipsychotic administration; however, several other medications are also associated with tardive dyskinesia. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM V) defines&#x000a0;tardive&#x000a0;dyskinesia&#x000a0;as a medication-induced movement disorder&#x000a0;that persists despite discontinuation or change of the medications. As per DSM-V, to confirm a diagnosis of&#x000a0;tardive&#x000a0;dyskinesia, symptoms must persist for at least one month after discontinuation of the medication.<xref ref-type="bibr" rid="article-29873.r1">[1]</xref><xref ref-type="bibr" rid="article-29873.r2">[2]</xref><xref ref-type="bibr" rid="article-29873.r3">[3]</xref></p>
        <p>Tardive dyskinesia is most common in people with schizophrenia and bipolar patients treated with antipsychotic medications but can occur in the setting of any disorder. In addition, the medications that precipitate tardive dyskinesia can also induce parkinsonian symptoms. Although the precise pathogenesis continues to elude researchers, data suggest that&#x000a0;tardive dyskinesia is induced by aberrant dopamine transporters.</p>
      </sec>
      <sec id="article-29873.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Tardive dyskinesia is caused due to long-term exposure to first and second-generation neuroleptics, certain antidepressants, lithium, and some antiemetic medications. Typically, the first-generation antipsychotics with increased dopamine D2 receptor affinity are affiliated with a higher risk of inducing tardive dyskinesia. Atypical antipsychotics have been associated with a decreased tardive dyskinesia diathesis--as well as fewer extrapyramidal side effects compared to typical antipsychotics--due to their lower affinity for dopamine D2 receptors in the dorsal striatum and concomitant blockade of serotonin 5-HT2A/2C receptors.<xref ref-type="bibr" rid="article-29873.r4">[4]</xref><xref ref-type="bibr" rid="article-29873.r5">[5]</xref></p>
        <p>Metoclopramide can also cause tardive dyskinesia, especially in older individuals.&#x000a0;The condition may also occur with certain antihistamines, amoxapine, and fluoxetine.</p>
      </sec>
      <sec id="article-29873.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The average prevalence of tardive dyskinesia is estimated at least 20% of all patients treated with first-generation neuroleptics. However, other medications responsible for tardive dyskinesia have been less studied, and published data indicate a prevalence ranging from 1% to 10%. Women risk developing tardive dyskinesia more than men, especially in middle-aged to senior patients. Post-menopausal women have incidence rates as high as 30% after almost a year of exposure to antipsychotic medications suggesting estrogen may have an antioxidant effect protecting against&#x000a0;tardive&#x000a0;dyskinesia. Elderly patients are more likely to develop&#x000a0;tardive&#x000a0;dyskinesia&#x000a0;due to age-related changes in the brain and body. Several studies indicate African Americans are more likely to develop&#x000a0;tardive&#x000a0;dyskinesia&#x000a0;after long-term exposure to dopamine-blocking agents than White-race individuals.<xref ref-type="bibr" rid="article-29873.r6">[6]</xref>&#x000a0;</p>
        <p>Other factors increasing tardive dyskinesia diathesis include the duration of exposure to the neuroleptic agent, the manifestation of EPS, and using first-generation antipsychotics--instead of second-generation antipsychotics. Of note, the long-term use of anticholinergic medications may increase the risk of tardive dyskinesia.&#x000a0;</p>
      </sec>
      <sec id="article-29873.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>First-generation antipsychotics bind more tightly to dopamine D2 receptors in comparison to second-generation antipsychotics, and for this reason,&#x000a0;the typical antipsychotics have a higher tendency to cause tardive dyskinesia. Some evidence suggests the presence of&#x000a0;extrapyramidal symptoms during neuroleptic treatment predicts the development of tardive dyskinesia. In addition to dopamine, the other neurotransmitter receptors that may be involved in causing tardive dyskinesia include 5-hydroxytryptophan receptors found in the striatum. These receptors interact with dopaminergic neurons and are considered to be involved in regulating motor activity.</p>
        <p>Upregulation of dopamine receptors due to chronic dopamine blockade can result in an exaggerated response to the postsynaptic receptors to dopamine, causing&#x000a0;tardive dyskinesia. Another hypothesis is the resulting oxidative stress due to antidepressants blocking dopamine receptors which causes an increase in dopamine metabolism, and this subsequently results in free radical production. The consequential oxidative stress on the basal ganglia--striatum and substantial nigra--results in the manifestation of&#x000a0;tardive dyskinesia. Evidence also suggests that antipsychotic medications and their metabolites can also be directly toxic to neurons through oxidative stress. It is known that&#x000a0;removing the agent that causes tardive dyskinesia can exacerbate the symptoms, and this is defined as withdrawal dyskinesia. It is theorized that this is due to dopamine D2 receptor upregulation and postsynaptic receptor super sensitivities. However, this does not explain why tardive dyskinesia remains for many years after the offending drug has been discontinued.<xref ref-type="bibr" rid="article-29873.r3">[3]</xref></p>
      </sec>
      <sec id="article-29873.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Physicians should examine all patients for any movement disorders before initiating treatment with dopamine D2 receptor antagonists. Tardive dyskinesia presents clinically as stereotypical involuntary movements of the tongue, neck, and facial muscles, truncal musculature, and limbs. Buccolingual movements, including masticatory muscles, are characterized by lip-smacking, tongue protrusion, perioral movements, chewing movements, or a puffing of cheeks. Sometimes these movements may be hard to distinguish from stereotype posturing seen in chronic psychotic patients. However,&#x000a0;tardive dyskinesia&#x000a0;is seen in patients with chronic exposure to dopamine D2 receptor blockade.</p>
        <p>The onset of tardive dyskinesia is insidious and can be difficult to distinguish as the nascent stages&#x000a0;demonstrate only subtle&#x000a0;deviant motion. Tardive&#x000a0;dyskinesia can manifest as early as 1 to 6 months following the initiation of a dopamine receptor antagonist. Diagnosis of acute or chronic dyskinesias may be challenging without a careful history. A thorough history of movement disorders and medication history will aid in diagnosing tardive dyskinesia accurately.&#x000a0;</p>
        <p>Specific&#x000a0;conditions that can occur with anti-dopaminergic agents include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tardive akathisia</p>
          </list-item>
          <list-item>
            <p>Tardive orofacial dyskinesia</p>
          </list-item>
          <list-item>
            <p>Tardive dystonia</p>
          </list-item>
          <list-item>
            <p>Tardive blepharospasm</p>
          </list-item>
          <list-item>
            <p>Tardive tics</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29873.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Numerous rating scales determine the presence and severity of&#x000a0;tardive dyskinesia. The most widely used instrument is the Abnormal Involuntary Movement Scale (AIMS). It is recommended to administer the AIMS at baseline before initiating antipsychotic medications, with a follow-up screening performed no longer than three months later. Upon evaluation of the patient, it can be noted that&#x000a0;tardive dyskinesia&#x000a0;is present at rest and somewhat diminished when there is any form of volitional movement. For example, tongue dyskinesias reduce when the patient is asked to protrude their tongue.</p>
        <p>If&#x000a0;tardive dyskinesia&#x000a0;is present in conjunction&#x000a0;with dementia, one should consider Huntington's disease, Wilson's disease, or a central nervous system tumor.&#x000a0;A diagnosis of antipsychotic-induced&#x000a0;tardive dyskinesia&#x000a0;is made after the symptoms have persisted for at least one month and required exposure to neuroleptics for at least three months. Tardive dyskinesia&#x000a0;should be distinguished from withdrawal dyskinesias as these most likely remit soon after the termination of the antipsychotic.&#x000a0;</p>
        <p>Workup for&#x000a0;tardive dyskinesia&#x000a0;may include selected laboratory studies and imaging. Typically, brain CT and MRI are normal in patients with&#x000a0;tardive dyskinesia. However, they may assist in&#x000a0;ruling out other conditions such as Huntington's disease, where atrophy of the caudate nucleus is seen, and Fahr syndrome, where calcification is noted in the basal ganglia.<xref ref-type="bibr" rid="article-29873.r1">[1]</xref><xref ref-type="bibr" rid="article-29873.r5">[5]</xref><xref ref-type="bibr" rid="article-29873.r7">[7]</xref></p>
      </sec>
      <sec id="article-29873.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Dopamine receptor antagonists should be avoided whenever possible&#x000a0;by selecting other medications that have a lower potential to cause&#x000a0;tardive dyskinesia. Furthermore, chronic use of first-generation antipsychotics should be avoided&#x000a0;whenever possible. To date, treatment options remain sparse. The American Academy of Neurology only recommends a few treatment options, which include clonazepam and ginkgo biloba. Valbenazine, a vesicular monoamine transport type 2 (VMAT2) inhibitor, was approved by the FDA on April 11, 2017, to treat tardive dyskinesia. The KINECT 3 trial results revealed valbenazine improved&#x000a0;tardive dyskinesia&#x000a0;when compared to the placebo drug. However, the best treatment option is primary prevention.<xref ref-type="bibr" rid="article-29873.r8">[8]</xref><xref ref-type="bibr" rid="article-29873.r9">[9]</xref><xref ref-type="bibr" rid="article-29873.r10">[10]</xref></p>
      </sec>
      <sec id="article-29873.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Chorea</p>
          </list-item>
          <list-item>
            <p>Complex seizure</p>
          </list-item>
          <list-item>
            <p>Essential tremor</p>
          </list-item>
          <list-item>
            <p>Tourette syndrome</p>
          </list-item>
          <list-item>
            <p>Tic disorder</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
          <list-item>
            <p>Sydenham&#x000a0;chorea</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29873.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Unfortunately, tardive dyskinesia is considered a chronic and unremitting disorder. Nothing has yet been proven to resolve tardive dyskinesia, but as mentioned previously, supportive measures can attenuate the severity.</p>
      </sec>
      <sec id="article-29873.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Tardive dyskinesia is primarily a progressive disturbance that causes unmeasurable discomfort and potential embarrassment. Fortunately, it is generally not life-threatening. However, severe tardive dyskinesia of the larynx and diaphragm may prove fatal.</p>
      </sec>
      <sec id="article-29873.s12" sec-type="Consultations">
        <title>Consultations</title>
        <list list-type="bullet">
          <list-item>
            <p>Ophthalmologist to assess the eye for Wilson&#x000a0;disease</p>
          </list-item>
          <list-item>
            <p>Neurologist</p>
          </list-item>
          <list-item>
            <p>Movement disorder specialist</p>
          </list-item>
          <list-item>
            <p>Psychiatrist consult</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29873.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The best means of obviating tardive dyskinesia is primary prevention. Primary prevention of&#x000a0;tardive dyskinesia&#x000a0;includes using the lowest effective dose of an antipsychotic agent for the shortest period possible. If&#x000a0;tardive dyskinesia&#x000a0;develops, it is recommended to decrease the dose or even discontinue the offending agent and switch to clozapine. Clozapine is recommended in patients with&#x000a0;tardive dyskinesia&#x000a0;who continue to require antipsychotics as the incidence of&#x000a0;tardive dyskinesia&#x000a0;with clozapine is significantly less than with other antipsychotics.</p>
      </sec>
      <sec id="article-29873.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The diagnosis and management of tardive dyskinesia are best made with an interprofessional team. In most cases, the primary clinician may suspect the diagnosis during follow-up. It is crucial to consult collaboratively with a pharmacist as part of the interprofessional team approach to managing the medication profile for patients who have developed tardive dyskinesia or are at risk for developing the condition.</p>
        <p>Movement disorders like tardive dyskinesias are&#x000a0;frequently aggravated by the use of drugs that block dopamine. In susceptible patients, even a single dose of an anti-dopaminergic drug can quickly develop disabling&#x000a0;movement disorders. Thus, besides the clinician, the role of the pharmacist is critical. Patients vulnerable to tardive dyskinesia include people with schizophrenia and those with developmental disabilities who may develop the movement disorder when administered a dopamine blocking agent. The pharmacist must note these patients and with which medications they are treated. The caregiver should be informed about the possibility of this adverse effect and the alternatives. Nursing can also monitor the patients for symptomatic improvement or decline and immediately report their observations to the prescriber and/or pharmacist to enact appropriate therapeutic interventions.</p>
        <p>Clinicians should be advised&#x000a0;not to start such medications if there are other options. Plus, the pharmacist must educate the patient about wearing an alert bracelet that warns against the administration of such drugs. Once the patient is started on neuroleptic, close monitoring is essential because with early diagnosis, the drug may be discontinued or the dose lowered to prevent full-blown tardive dyskinesia.<xref ref-type="bibr" rid="article-29873.r11">[11]</xref><xref ref-type="bibr" rid="article-29873.r12">[12]</xref>&#x000a0;[Level&#x000a0;5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Data on the management of tardive dyskinesia are inconsistent and difficult to understand. Some studies show an improvement when the antipsychotic drug is decreased in dose or discontinued, and other studies show no change. Long-term studies suggest that tardive dyskinesia persists at tardive dyskinesia persists in at least 10&#x000a0;to 30% of patients. Recent studies show that the outcomes of tardive dyskinesia are improved in younger patients treated with low doses for shorter periods. Switching to low potency antipsychotic drugs has been shown to lower the risk of tardive dyskinesia. Recently the FDA approved the drug valbenazine to treat tardive dyskinesia. Early data from the clinical trial reveals that the drug effectively alleviates&#x000a0;tardive dyskinesia and is safe. However, the study was conducted by many physicians who also received some&#x000a0;type of&#x000a0;compensation from the pharmaceutical companies- so one has to take this data with a grain of salt until more long-term data are available.<xref ref-type="bibr" rid="article-29873.r2">[2]</xref><xref ref-type="bibr" rid="article-29873.r13">[13]</xref>&#x000a0;[Level&#x000a0;5]</p>
      </sec>
      <sec id="article-29873.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29873&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29873">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/tardive-dyskinesia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29873">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29873/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29873">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29873.s16">
        <title>References</title>
        <ref id="article-29873.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Abreu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.</article-title>
            <source>Tremor Other Hyperkinet Mov (N Y)</source>
            <year>2018</year>
            <volume>8</volume>
            <fpage>570</fpage>
            <pub-id pub-id-type="pmid">30191087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>JWY</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carleton</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Honer</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Procyshyn</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review.</article-title>
            <source>CNS Drugs</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>917</fpage>
            <page-range>917-938</page-range>
            <pub-id pub-id-type="pmid">30121819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Citrome</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic-Related Movement Disorders: Drug-Induced Parkinsonism vs. Tardive Dyskinesia-Key Differences in Pathophysiology and Clinical Management.</article-title>
            <source>Neurol Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-248</page-range>
            <pub-id pub-id-type="pmid">30027457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erbe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Prevention and Treatment of Antipsychotic-induced Tardive Dyskinesia].</article-title>
            <source>Fortschr Neurol Psychiatr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>217</fpage>
            <page-range>217-224</page-range>
            <pub-id pub-id-type="pmid">29996156</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walther</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stegmayer</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Diagnosis and treatment of motor phenomena in schizophrenia spectrum disorders].</article-title>
            <source>Ther Umsch</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">29909765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and Prevention of Tardive Dyskinesia.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <season>Nov/Dec</season>
            <volume>78</volume>
            <issue>9</issue>
            <fpage>e1426</fpage>
            <pub-id pub-id-type="pmid">29345874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
            </person-group>
            <article-title>Tardive Dyskinesia: Recognition, Patient Assessment, and Differential Diagnosis.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2018</year>
            <season>Mar/Apr</season>
            <volume>79</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29570969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Nierenberg</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Sajatovic</surname>
                <given-names>M</given-names>
              </name>
              <collab>Tardive Dyskinesia Assessment Working Group</collab>
            </person-group>
            <article-title>Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskinesia Assessment Workshop.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2018</year>
            <season>May/Jun</season>
            <volume>79</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">29742330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Levien</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>VMAT2 Inhibitors: New Drugs for the Treatment of Tardive Dyskinesia.</article-title>
            <source>Consult Pharm</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-209</page-range>
            <pub-id pub-id-type="pmid">29609698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caroff</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Aggarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yonan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.</article-title>
            <source>J Comp Eff Res</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>135</fpage>
            <page-range>135-148</page-range>
            <pub-id pub-id-type="pmid">28965423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <collab>Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders</collab>
            <article-title>Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.</article-title>
            <source>Aust N Z J Psychiatry</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>39</volume>
            <issue>1-2</issue>
            <fpage>1</fpage>
            <page-range>1-30</page-range>
            <pub-id pub-id-type="pmid">15660702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munetz</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>How to examine patients using the Abnormal Involuntary Movement Scale.</article-title>
            <source>Hosp Community Psychiatry</source>
            <year>1988</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1172</fpage>
            <page-range>1172-7</page-range>
            <pub-id pub-id-type="pmid">2906320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29873.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Essali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soares-Weiser</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Calcium channel blockers for antipsychotic-induced tardive dyskinesia.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>26</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD000206</fpage>
            <pub-id pub-id-type="pmid">29578611</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
